Biocon Limited

rs,

7, 2023 To, The Secretary BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code - 532523 Dear Sir/Madam, Subject: Investor Presentati

₹11,550

our Core Values Collaboration, Teamwork & Mutual Respect Building Biocon Biocon at a Glance ₹11,550 Cr | $ ~1.4 bn Revenue* ~16,500+ Total Employees* Rank #8 Among Top 10 Global Biotech, Pharma &

rs 8

se global talent pool of 5,500+ people 390+ patents granted Portfolio comprises 20 biosimilars 8 Commercial Products in Global Markets 5.5M+ Patients served Unique, fully integrated leading g

rs 1

products commercialized globally Hybrid model: Direct presence + Network of partners & distributors 1Two products are in-licensed i.e. Adalimumab & Etanercept Biosimilars: Leading global player with a

57%

of care ✓ In Ph 1 HNSCC trials, BCA101 demonstrated a strong clinical profile, including an ORR of 57%, CR rate of 18%, mPFS of at least 6.2mos, and a well-tolerated safety profile ✓ Strong scientifi

18%

HNSCC trials, BCA101 demonstrated a strong clinical profile, including an ORR of 57%, CR rate of 18%, mPFS of at least 6.2mos, and a well-tolerated safety profile ✓ Strong scientific rationale suppor

38%

apeutics ✓ $190M raised to date from syndicate of dedicated biotech investors. Biocon ownership at 38%, to reduce to ~23% in FY24. ✓ Leveraging the Biocon and Syngene infrastructure to offer agility

23%

sed to date from syndicate of dedicated biotech investors. Biocon ownership at 38%, to reduce to ~23% in FY24. ✓ Leveraging the Biocon and Syngene infrastructure to offer agility and deep experience i

1,100 %

FY24 Consolidated (in ₹ Cr.) Q2 FY24 Q2 FY23 YoY % Total Revenue 3,620 2,384 Core EBITDA1 1,100 % Margin EBITDA % Margin Profit Before Tax (Before exceptional charge) % Margin Net Profit (Bef

32%

(Before exceptional charge) % Margin Net Profit (Before exceptional charge) Net Profit Margin % 32% 900 25% 238 7% 142 4% 815 35% 535 22% 246 10% 168 7% 52 35 68 (3) Biosimilars +9

25%

ceptional charge) % Margin Net Profit (Before exceptional charge) Net Profit Margin % 32% 900 25% 238 7% 142 4% 815 35% 535 22% 246 10% 168 7% 52 35 68 (3) Biosimilars +97% | Resea

7%

charge) % Margin Net Profit (Before exceptional charge) Net Profit Margin % 32% 900 25% 238 7% 142 4% 815 35% 535 22% 246 10% 168 7% 52 35 68 (3) Biosimilars +97% | Research +18%

Research

2

Exceptional items

1

Research

Discovery Services Provide end-to-end therapeutic discovery capabilities including differentiating research technologies and platforms, across many disciplines, disease areas and therapeutic modalities Development and Manufacturing Services – Small Molecules Leverage existing capabilities to offer integrated Chemistry, Manufacturing, and Controls (CMC) solutions Secure U.S. FDA and other major global regulatory approvals for the small molecule commercial scale manufacturing facility as a platform to attract a broader scope of projects

Research

Dedicated Centers Continue to strengthen our existing partnerships with Amgen, Bristol Myers Squibb (BMS) and Baxter through the dedicated centers which provide: a strong foundation for future planning; revenue visibility over the medium to long term; and predictable cash flows Scaling up Manufacturing Services Development and Manufacturing Services – Large Molecules Drive an integrated approach for biologics development and manufacturing to provide a one-stop- shop capability from drug discovery to commercial manufacturing for biologics Accelerate capacity build-up Operational Excellence Focus on customer delivery through operational excellence People Develop strong leaders and managers while offering all employees career- long learning opportunities Environmental, Social and Governance (ESG) Committed to operating in a responsible and sustainable manner. Q2 FY24 Highlights Financial Highlights: Q2 FY24 Consolidated (in ₹ Cr.) Q2 FY24 Q2 FY23 YoY % Total Revenue 3,620 2,384 Core EBITD

Exceptional items

• Q2 FY24 • PLI accrual reversal for last year • Stelis acquisition related expenses Exceptional Items (net of tax and minority interest) (16) (122) • Q2 FY23 • Deal related expenses of the Viatris transaction • MAT credit balance charge on adoption of new tax regime of 25% Net Profit (Reported) 126 47 168 Biocon Generics: Q2 FY24 Highlights Performance driven by continued traction in our US generic formulations business and expansion in MoW markets. API business performance muted. Announced a partnership agreement with Juno Pharmaceuticals for the commercialization of Liraglutide in Canada In ₹ Cr Q2 FY24 Q2 FY23 YoY % Segment Revenue 676 652 4 22 Acquired U.S. FDA approved oral solid dosage facility of Eywa Pharma Inc. PBT Received seven generic formulations approvals across markets. Two API approvals each, received in the U.S. and EU % of revenue 66 10 54 8 Process validation at the Company’s greenfield immunosuppressant API facility in Visakhapatnam successfully completed Expect su